AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 2,515 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 2,515 shares of AnaptysBio stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $112,445.65. Following the completion of the transaction, the chief financial officer owned 21,852 shares in the company, valued at $977,002.92. The trade was a 10.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dennis Mulroy also recently made the following trade(s):

• On Wednesday, January 7th, Dennis Mulroy sold 1,908 shares of AnaptysBio stock. The shares were sold at an average price of $45.11, for a total value of $86,069.88.
• On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $145,483.38.
• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The stock was sold at an average price of $50.00, for a total transaction of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25.

AnaptysBio Price Performance

NASDAQ ANAB traded up $0.87 on Friday, hitting $44.67. 591,811 shares of the stock were exchanged, compared to its average volume of 739,267. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $52.47. The company’s 50-day moving average price is $42.62 and its two-hundred day moving average price is $31.46. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -15.84 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The business had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. Equities analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC grew its position in shares of AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 18,165 shares during the last quarter. Woodline Partners LP increased its position in AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after buying an additional 305,950 shares during the period. Rhumbline Advisers increased its position in AnaptysBio by 2.7% in the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after buying an additional 826 shares during the period. Voya Investment Management LLC acquired a new position in shares of AnaptysBio during the first quarter worth approximately $1,803,000. Finally, HighMark Wealth Management LLC boosted its position in shares of AnaptysBio by 58.2% in the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after acquiring an additional 53,550 shares during the period.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Analysts Set New Price Targets

A number of research firms recently issued reports on ANAB. UBS Group began coverage on AnaptysBio in a research report on Wednesday. They set a “buy” rating and a $70.00 price objective for the company. Truist Financial lifted their price target on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a report on Monday, November 10th. Stifel Nicolaus dropped their price objective on AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Finally, HC Wainwright reduced their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.